Management ChangeJun 30, 2026, 08:01 AM
ALX Oncology Appoints Scott Garland as Chairman, Michael Listgarten as GC
AI Summary
ALX Oncology Holdings Inc. announced key leadership changes, appointing Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel, effective immediately. Mr. Garland, who has been on the board since November 2022, succeeds co-founder Corey Goodman, Ph.D., who is stepping down after more than a decade. The company highlights the extensive industry experience of both new appointees, aiming to strengthen its leadership as it advances its clinical pipeline.
Key Highlights
- Scott Garland appointed Chairman of the Board of Directors, effective immediately.
- Michael Listgarten appointed General Counsel, effective immediately.
- Mr. Garland has served on the ALX Oncology Board since November 2022.
- Corey Goodman, Ph.D., steps down as Chairman and Board member after over a decade.
- Mr. Garland brings over 30 years of biopharmaceutical industry knowledge.
- Mr. Listgarten brings over 30 years of legal experience in biopharma.
Price Impact
More from ALXO